MipSalus develops treatments for severe, rare amino acid metabolism disorders. First drug in our pipeline is Phelimin for the treatment of Phenylketonuria, PKU. Phelimin is an oral, non-systemic drug that will allow PKU patients to eat normal food and live normal lives. Phelimin has received orphan drug designations from both EMA and FDA.
Our medicinal products are based on our proprietary Molecular Imprinted Polymers (MIP) technology platform. We use MIPs to bind specific pathogenic amino acids in the gastrointestinal tract.
The name “MipSalus” is a combination of MIP and “Salus” which is the name of the ancient Roman goddess of health and prosperity. In other words; MipSalus’ mission is to use the MIPs technology for healthcare purposes.
To ensure optimal efficiency and flexibility MipSalus is a slim core organization supplemented with close collaboration with relevant private subcontractors and universities.
MipSalus ApS was founded in 2006 and funded solely by private investors.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Agern Allé 3, Hørsholm,dk-2970,denmark
- Phone
- 45 36 92 16 40
- in****@****alus.dk
- Industry
- Biotechnology
- Website
- mipsalus.dk
- HQ
- Hørsholm
Mipsalus Aps Questions
Mipsalus Aps's helpline number is 45 36 92 16 40
Mipsalus Aps's website is mipsalus.dk
Mipsalus Aps's LinkedIn profile is https://dk.linkedin.com/company/mipsalus-aps
Mipsalus Aps has
6 employees.
View email and phone details for 6
employees at Mipsalus Aps.
Mipsalus Aps's industry is
Biotechnology
Mipsalus Aps's top competitors are
Nanovi A/s,
Tridem Bioscience,
Combotope Therapeutics Aps,
Chreto - A Paradigm Shift In Mab Purification,
Biocamino Aps,
Cytovac Ab,
Expres2ion Biotechnologies,
Neumirna Therapeutics,
Upfront Chromatography A/s,
Gubra.
Mipsalus Aps's support email address is info@mipsalus.dk
Mipsalus Aps's categories are Biotechnology
Mipsalus Aps's founding year is 2006
